drugset / Trial / NCT00002565

Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma

NCT00002565

RandomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective for intermediate-grade or immunoblastic non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have intermediate-grade or immunoblastic non-Hodgkin's lymphoma.

Timeline

Start
1994-05-25
Primary completion
2007-02-05
Completion
2007-02-05

Drugs

EvaluationDrugModalityDoseRoute
Subject 2-MERCAPTOETHANESULFONIC ACID Small molecule
Subject Bleomycin Unknown
Subject Cisplatin Other / unclassified
Subject Cytarabine Small molecule
Subject Doxorubicin Other / unclassified
Subject Etoposide Small molecule
Subject Idarubicin Small molecule
Subject Ifosfamide Small molecule
Subject Methylprednisolone Other / unclassified
Subject Mitoxantrone Small molecule
Subject Prednisone Other / unclassified
Background Cyclophosphamide Other / unclassified
Background Vincristine Small molecule

Indications